Investors

Recent Releases

May 1, 2024

Emergent BioSolutions Reports First Quarter 2024 Financial Results

First Quarter 2024 Total Revenues of $300.4 million , above the prior guidance range First Quarter 2024 Net Income of $9.0 million and Adjusted EBITDA of $66.9 million Updates FY 2024 guidance GAITHERSBURG, Md. , May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc.

May 1, 2024

Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position

Proactive changes aim to ensure long-term sustainability and growth, optimize operations, streamline processes, and allocate resources more efficiently Reorganization will align with evolving business goals, strategic priorities and new operational plan Overall efforts expected to deliver annual

May 1, 2024

Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone

Nearly 9 in 10 Americans surveyed agree opioid overdoses are a concern for teenagers and college students; parents in the survey want life-saving treatment to be easily accessible in case of an emergency GAITHERSBURG, Md. , May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc.